// App-Quantinova.ai

213 : Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.

Researchers

Presenter

  • Guru Sonpavde

Principal Investigators

  • Gregory Russell Pond

  • Arnoud J. Templeton

  • Eugene D. Kwon

  • Johann S. De Bono

Medical Centers

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • Ontario Clinical Oncology Group, Hamilton, ON, Canada

  • Kantonsspital St Gallen, St Gallen, Switzerland

  • Mayo Clinic, Rochester, MN

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Locations

  • United States

  • Canada

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved